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Abstract
Introduction: Demyelinated axons in multiple sclerosis (MS) lesions have an increased energy demand in order to
maintain conduction. However, oxidative stress-induced mitochondrial dysfunction likely alters glucose metabolism
and consequently impairs neuronal function in MS. Imaging and pathological studies indicate that glucose metabolism
is altered in MS, although the underlying mechanisms and its role in neurodegeneration remain elusive. We
investigated expression patterns of key enzymes involved in glycolysis, tricarboxylic acid (TCA) cycle and lactate
metabolism in well-characterized MS tissue to establish which regulators of glucose metabolism are involved in MS
and to identify underlying mechanisms.
Results: Expression levels of glycolytic enzymes were increased in active and inactive MS lesions, whereas expression
levels of enzymes involved in the TCA cycle were upregulated in active MS lesions, but not in inactive MS lesions. We
observed reduced expression and production capacity of mitochondrial α-ketoglutarate dehydrogenase (αKGDH) in
demyelinated axons, which correlated with signs of axonal dysfunction. In inactive lesions, increased expression of
lactate-producing enzymes was observed in astrocytes, whereas lactate-catabolising enzymes were mainly
detected in axons. Our results demonstrate that the expression of various enzymes involved in glucose
metabolism is increased in both astrocytes and axons in active MS lesions. In inactive MS lesions, we provide
evidence that astrocytes undergo a glycolytic shift resulting in enhanced astrocyte-axon lactate shuttling, which
may be pivotal for the survival of demyelinated axons.
Conclusion: In conclusion, we show that key enzymes involved in energy metabolism are differentially expressed in
active and inactive MS lesions. Our findings imply that, in addition to reduced oxidative phosphorylation activity, other
bioenergetic pathways are affected as well, which may contribute to ongoing axonal degeneration in MS.
Keywords: Glycolysis, TCA cycle, lactate shuttle, αKGDH, Neurodegeneration
Introduction
Multiple sclerosis (MS) is an immune-mediated disease of
the central nervous system where macrophages and T-
cells infiltrate the brain and induce widespread
demyelination [15]. Over time, the number of newly-
formed lesions decreases and disease progression seems to
be mainly driven by axonal dysfunction and neuronal de-
generation [13]. Evidence is emerging that mitochondrial
dysfunction and associated oxidative stress play an im-
portant role in driving neurodegeneration [25, 47].
Demyelinated axons have to consume more energy to
maintain conduction [42]. As a result, axons in MS lesions
contain more mitochondria, but, strikingly, lower oxidative
phosphorylation (OxPhos) activity and increased numbers
of mtDNA deletions in the neuronal cell bodies, indicating
that mitochondria are damaged and dysfunctional [8, 46].
The OxPhos system is the last step in glucose metabolism
and is critically dependent on glycolysis and the tricarb-
oxylic acid (TCA) cycle to provide the electrons needed to
maintain a proton gradient and to produce ATP. MS
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patients have elevated levels of essential glucose metabolites
in the cerebrospinal fluid (CSF), serum and the brain as
compared to non-neurological controls [39, 41, 50]. Al-
though it remains difficult to determine which cells are
responsible for these changes in the patient’s fluids, these
studies illustrates that bioenergetic changes likely occur in
MS patients. Moreover, glucose and lactate levels are
increased in MS lesions, as determined with positron emis-
sion tomography (PET) and magnetic resonance spectros-
copy (MRS) [39, 40]. Taken together, there is ample
evidence that glucose metabolism is altered in MS brain
tissue and may play an important role in driving
neurodegeneration.
To date, most studies have focussed on OxPhos activity
and several studies demonstrated profound defects in
OxPhos activity in MS. Yet, surprisingly little is known
about the expression of enzymes involved in glycolyis and
TCA cycle flux in MS tissue. Glycolysis is the metabolic
pathway in which glucose is metabolised into pyruvate by
various enzymes, including the rate-limiting enzymes hexo-
kinase (HK) and pyruvate kinase (PK) [2]. There are three
different isoforms of HK of which hexokinase 2 (HK2) has
been shown to be the principal regulated isoform [48]. HK2
rapidly phosphorylates glucose into glucose-6-phosphate,
which is the initial step of the glycolysis, while the final step
of the glycolysis is catalysed by PK [48, 49]. Pyruvate
produced by glycolysis can be transported into mitochon-
dria where it is converted into acetyl-CoA by pyruvate
dehydrogenase (PDH) to fuel the TCA cycle. Two other
rate - limiting TCA cycle enzymes are α-ketoglutarate
dehydrogenase (αKGDH) and malate dehydrogenase
(MDH), both producing NADH [17, 19, 33]. NADH is the
most important driving force of OxPhos, intimately linking
TCA cycle metabolism and OxPhos.
In addition to glucose, lactate can serve as an
important energy source in the brain. Lactate can be
produced from pyruvate by lactate dehydrogenase (LDH),
which forms 5 different multiprotein complexes consisting
of the products of two genes; LDHA and LDHB. The
different complexes vary in the abundance of LDHA and
LDHB. LDHA is mainly involved in the conversion of
pyruvate into lactate, whereas LDHB preferably generates
pyruvate from lactate [26].
It has been proposed that lactate secreted by astrocytes
via specific monocarboxylate transporters (MCT) can be
taken up and oxidized into pyruvate by neighbouring cells
[36]. This metabolic coupling, known as the astrocyte-
neuron lactate shuttle (ANLS), seems to be of particular
importance in grey matter [34]. In white matter, oligoden-
drocytes rather than astrocytes supply axons with lactate
via MCT1, which is essential for proper axonal function
[16, 22].
Brain glucose metabolism is subjected to changes
during aging and an altered glucose metabolism has
been suggested to contribute to neurodegenerative dis-
orders including Alzheimer’s disease (AD) and Huntington
disease (HD) [11, 20]. It has been shown that the activity
and expression of various metabolic enzymes was altered in
the brain of AD patients [5, 7, 37]. Experimental studies
have demonstrated that increased glycolytic activity induces
a pro-inflammatory phenotype in astrocytes and can induce
cell death in neuronal cells [38, 44]. Moreover, reduced
activity of specific TCA cycle enzymes such as PDH and
αKGDH, have been associated with neurodegeneration
[32, 43]. These studies illustrate the impact of altered
glycolysis and TCA cycle function on brain function-
ality and neurodegeneration.
To unravel the mechanisms underlying neurodegener-
ation in MS, we aimed to gain more insight into glucose
metabolism in MS lesions. We show that expression of
glycolytic and TCA cycle enzymes is highly increased in
active MS lesions. In inactive MS lesions, astrocytes
evidently increase the expression of key glycolytic and
lactate-producing enzymes, whereas axons mainly
upregulate lactate-catabolising enzymes. Finally, we
observed reduced expression and reduced NADH pro-
duction capacity of mitochondrial αKGDH in demyeli-
nated axons, which correlates with axonal dysfunction.
Taken together, we provide evidence for increased gly-
colysis, increased astrocyte-axon lactate coupling and
decreased axonal mitochondrial function in MS, which
may contribute to the ongoing axonal degeneration.
Materials and methods
Brain tissue
Brain paraffin tissue samples of 14 MS patients and 4
non-neurological controls were obtained in collaboration
with the Netherlands Brain Bank, Amsterdam, The
Netherlands (coordinator Dr. I. Huitinga). In addition,
frozen tissue blocks were obtained from 6 MS patients
and 3 non-neurological controls for histochemical analysis.
Detailed clinical data are summarized in Table 1. The study
was approved by the institutional ethics review board (VU
University Medical Center, Amsterdam, The Netherlands)
and all donors or their next of kin provided written
informed consent for brain autopsy, use of material and
clinical information for research purposes. Lesion types
were determined by Proteolipid protein (PLP) and MHCII
staining and are summarized in Table 1.
Immunohistochemistry
Immunohistochemistry was performed as described previ-
ously [29]. In short, 5 μm-thick paraffin sections were
deparaffinised in a series of xylene and ethanol. Endogen-
ous peroxidase activity was blocked by incubating the sec-
tions in methanol containing 0.3 % H2O2 for 30′ and the
antigens were retrieved in citrate buffer (pH 6). Primary
antibodies (see Additional file 1: Table S1) were diluted in
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phosphate-buffered saline (PBS) supplemented with 1 %
bovine serum albumin (BSA; Roche Diagnostics, Mann-
heim, Germany) and 0.05 % Tween-20 (SigmaAldrich, St.
Louis, MO) and the sections were incubated overnight at
4 °C. The next day, sections were incubated for 30′ with
EnVision secondary antibody coupled with horseradish per-
oxidase (DAKO, Glostrup, Denmark) followed by 10′ incu-
bation in the presence of 3,3′diaminobenzidine-
tetrahydrochloridedihydrate (DAB; DAKO). Sections were
washed in PBS for at least 3 × 5′ in between steps. Sections
were counterstained with haematoxylin for 1’, rinsed with
tap water and dehydrated in a series of ethanol and xylene
and mounted with Entellan (Merck, Darmstadt, Germany).
Negative controls were essentially blank. DAB stainings
were semi-quantitatively, independently and blind analyzed
by PN and JvH.
Fluorescence immunohistochemistry was applied to
indentify cellular localization patterns. For this purpose,
deparaffinised sections were incubated for 20′ in PBS con-
taining 1 % BSA, 0.05 % Tween-20 and 10 % normal goat
serum followed by incubation with primary antibodies.
Alexa Fluor® (Life Technologies, Vienna, Austria) labelled
secondary antibodies were used for fluorescence labelling.
To reduce autofluorescence, sections were counterstained
with Sudan Black (0.3 % in 70 % ethanol) (SigmaAldrich).
Finally, sections were stained with Hoechst (diluted
1:1.000) (Life Technologies) to visualize cellular nuclei and
mounted with mounting medium (DAKO). Images were
taken using a confocal microscope (TCS SP2, Leica Micro-
systems, Mannheim, Germany) equipped with an Ar/Kr
laser (488 nm) and 3 HeNe lasers (543, 594 and 633 nm).
In order to quantify axonal colocalization, 9 images of the
active rim and 9 images of the inactive lesion center were
obtained, each of 3 different MS patients. All images were
taken with a 40x objective except the images of αKGDH
expression in axonal mitochondria which were taken with a
Table 1 Clinical data of MS patients and non-neurological controls
Case Age
(years)





1 51 SP m 11:00 >15 A P/F
2 56 SP m 8:00 27 CA P
3 49 RR-SP m 8:00 25 CA P
4 66 SP f 6:00 23 CA P/F
5 54 ND m 8:30 ND CA P
6 66 PP m 7:30 26 CA P
7 41 PP m 7:23 14 A P
8 54 ND m 8:30 15 A P
9 75 RR-SP m 7:45 24 CIA P
10 70 SP f 6:55 40 CIA P
11 44 PP m 12:00 16 CA, A P
12 50 RR-SP f 7:35 17 CA P
13 61 SP m 9:15 14 CA P
14 64 RR-SP f 10:10 38 CIA P
15 70 RR-SP m 7:45 46 CIA F
16 77 PP m 4:15 26 A F
17 48 SP f 11:40 23 CIA F
18 56 SP m 10:10 13 CA F
19 84 control f 6:55 NA NA P
20 56 control m 9:15 NA NA P
21 62 control m 7:20 NA NA P
22 82 control m 6:20 NA NA P
23 55 control m 7:30 NA NA F
24 76 control m 6:45 NA NA F
25 70 control f 6:15 NA NA F
SP secondary progressive MS, PP primary progressive MS, ND not determined, NA not applicable, m male, f female, A active lesion, CA chronic active lesion, CIA
chronic inactive lesion, P paraffinembedded tissue, F frozen tissue
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63x objective. The images were analyzed with ImageJ
software, using the intensity correlation plug-in [23].
Quantitative enzyme histochemistry
Frozen sections (5 μm) were stained using metabolic
mapping to visualize NAD+-dependent activity of lactate
dehydrogenase (LDH; EC number 1.1.1.27) and αKG
dehydrogenase (αKGDH; EC number 1.2.4.2). Quantita-
tive enzyme activity experiments were conducted and
analyzed as described previously [9, 28]. Incubation in
the presence of appropriate substrate and cofactors was
performed at 37 °C for 60'. Control reactions were per-
formed in the absence of substrate, but in the presence
of cofactors to control for non-specific enzyme activity
staining [9, 28].
Monochromatic images were taken from the active
rim (N = 12) and inactive lesion center (N = 15) of 5
different MS patients for quantification using the Nu-
ance® spectral imager (PerkinElmer, Waltham, MA) at a
wavelength of 585 nm. The total area positively stained
was calculated using ImageJ software. Control reactions
for LDH were essentially blank. αKGDH activity was
relatively low resulting in higher background staining.
Therefore, the total area measured in control sections
was subtracted from the total area positively stained in
the presence of the substrate.
Cell culture and treatment
The human neuroblastoma cell line SH-SY5Y was
cultured in DMEM/F12 (1:1, Life Technologies) con-
taining 10 % fetal calf serum (FCS, Life Technologies),
2 mM L-glutamine (Life Technologies), and penicillin/
streptomycin (50 mg/ml; Life Technologies) in 5 %
CO2 at 37 ° C. Various treatment strategies were used
to unravel neuronal αKGDH regulation. Cells were
cultured for 24 h in glucose-free medium supple-
mented with 25 mM or 5 mM glucose to generate
hypoglycaemic conditions. Alternatively, confluent
SH-SY5Y cells were cultured in a hypoxic chamber in
the presence of 2 % oxygen for 24 h. Finally, cells
were exposed to 25 μM tert-butyl hydrogen peroxide
(tbH2O2) (SigmaAldrich) or tumour necrosis factor α
(TNF-α) and interferon γ (IFN-γ) (5 ng/ml; Peprotech,
Rocky Hill, NJ) for 24 h.
RNA isolation and quantitative PCR
Total RNA from SH-SY5Y cells was isolated using Trizol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. cDNA was synthesized with the high-capacity
cDNA reverse transcription kit (Applied Biosystems, Foster
City, CA) following manufacturer’s guidelines. Quantitative
PCR (qPCR) reactions were performed in a step-one
sequence detection system using the SYBR Green method
(Applied Biosystems) as described previously [27]. mRNA
expression levels were normalized to the household gene
XPNPEP1 (Qiagen, Venlo, the Netherlands) expression
levels [12]. αkGDH primers (forward: GGGATTTTG
GATGCTGATCTG, reverse: AGTGGAAGACCTTGTC
GAG) were synthesized by Invitrogen.
Statistical analysis
One-way ANOVA with Bonferroni post-hoc test was used
to assess differences in colocalization between the normal
appearing white matter (NAWM), active rim and inactive
lesion center. The student’s t-test was used to assess differ-
ences in the level of enzyme staining intensity in active
and inactive MS lesions (Fig. 3j), αKGDH staining (Fig. 5I)
and αKGDH activity (Fig. 5l). Linear regression analysis
was used to determine the correlation between TCA cycle
gene expression and disease duration.
Results
Increased expression of key glycolytic enzymes in active
and inactive MS lesions
Active MS lesions are characterized by the presence of
densely packed macrophages throughout the lesion area,
whereas inflammation has abated in inactive MS lesions
(Additional file 2: Figure S1). Expression of HK2 and PK
was strikingly upregulated in both active and inactive
MS lesions as compared to surrounding normal appear-
ing white matter (NAWM), and predominantly localized
in reactive astrocytes (Fig. 1a-f ). Marked differences
were not observed in HK2 and PK immunoreactivity
between control white matter and NAWM (data not
shown). HK2 and PK staining intensity in MS lesions as
compared to NAWM was semi-quantitatively scored
and revealed a striking increase in HK2 and PK immu-
noreactivity in both active and inactive MS lesions as
compared to NAWM (Fig. 1g). Chronic active lesions
are characterized by a rim of activated microglia and
macrophages and a center devoid of inflammatory cells
(Additional file 2: Figure S1). The expression pattern
and staining intensity of HK2 and PK in the active rim
of chronic active lesions was comparable to that ob-
served in active lesions. Likewise, HK2 and PK expres-
sion levels in the inactive center of chronic active lesions
were similar as observed in inactive lesions (data not
shown). Sections containing chronic active lesions were
used to quantify the cellular colocalization of metabolic
enzymes allowing the comparison between active and
inactive lesion within the same section. Immunofluores-
cence double labelling of neurofilament and HK2 and
PK showed significantly increased HK2 and PK expres-
sion in demyelinated axons, most notably in the inactive
center of chronic active MS lesions (Fig. 2).
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Increased astrocyte-axon lactate coupling in inactive MS
lesions
Increased expression of HK2 and PK in inactive MS
lesions is indicative of a high glycolytic rate, which is
generally associated with increased production and
secretion of lactate [45, 48]. Therefore, we aimed to
determine lactate production in MS lesions. Lactate is
produced by LDH, which forms a multiprotein complex
consisting of LDHA and LDHB. LDHA is responsible for
lactate production and LDHB for lactate utilization.
LDHA and LDHB immunoreactivity was evidently in-
creased in active MS lesions as compared to surround-
ing NAWM. Anti-LDHA and anti-LDHB antibodies
predominantly decorated astrocytes (Fig. 3a-b,d-e).
LDHA and LDHB expression levels were comparable
in inactive lesions and NAWM (Fig. 3c,f ). Using quan-
titative enzyme histochemistry, we found that the
activity of lactate utilization by LDH was highly
increased in active lesions, but decreased in inactive
lesions (Fig. 3g-j). Next, we determined the ratio of
LDHA/LDHB expression in MS lesions in order to
determine whether lactate is rather produced or utilized
in astrocytes and axons. The astrocytic LDHA/LDHB
ratio was increased in inactive lesions compared to the
NAWM (Fig. 3k). In contrast, the ratio of LDHA/LDHB
immunoreactivity was decreased in axons in the inactive
Fig. 1 HK2 and PK expression in MS lesions. HK2 and PK are weakly expressed throughout the NAWM (a, d). Expression of both HK2 and PK was
more pronounced in active and inactive MS lesions (b-c, e-f). Insets show immunofluorescence labelling of GFAP (red) and HK2 (green, b-c) or
PK (green, e-f) indicating that astrocytes in MS lesions express high levels of HK2 and PK. Staining intensity of HK2 and PK2 in MS lesions was
increased as compared to NAWM in the same section (g). +/− = similar staining intensity as compared to NAWM, + = increased staining intensity
as compared to NAWM, ++ = strongly increased staining intensity as compared to NAWM
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lesion center of MS lesions as compared to NAWM
(Fig. 3l). Thus, in inactive MS lesions, astrocytes express
more lactate-producing enzymes, whereas axons express
more lactate-degrading enzymes.
Under normal conditions oligodendrocytes supply axons
with lactate [16, 22]. Here, we hypothesized, that in the
absence of oligodendrocytes, astrocytes provide demyeli-
nated axons with lactate. We previously described that
astrocytes in inactive MS lesions express increased levels
of MCT1, which is involved in the secretion of lactate
[29]. Axons require MCT2 to take up lactate. Here we
found that MCT2 is expressed by demyelinated axons that
are in close contact with astrocytes (Fig. 3m-p) [29].
In summary, our data demonstrates increased expres-
sion of glycolytic and lactate-producing enzymes in astro-
cytes in the inactive center of chronic active MS lesions.
Demyelinated axons have increased expression of lactate-
consuming enzymes and are able to take up lactate.
Increased expression of key TCA cycle enzymes in active
MS lesions
Expression of TCA cycle enzymes PDH, αKGDH and
MDH was consistently increased in active MS lesions
as compared to surrounding NAWM and is localized
predominantly in astrocytes (Fig. 4a-b, d-e, g-h). No
marked differences were observed in PDH, αKGDH
and MDH immunoreactivity between control white
matter and NAWM (data not shown). Expression levels
of PDH and αKGDH were similar in inactive MS
lesions and NAWM (Fig. 4c,f ). In contrast, MDH
immunostaining was slightly increased in inactive le-
sions compared to NAWM (Fig. 4i). Semi-quantitative
analysis demonstrated that expression of TCA cycle
enzymes was increased specifically in active MS lesions
(Fig. 4j). The staining intensity of PDH, αKGDH and
MDH in inactive MS lesions correlated with disease
duration (Fig. 4k), but was independent of the age of
the patient or MS type (Additional file 3: Figure S2).
Axonal localization of both PDH and MDH was
increased in the active rim and inactive lesion center
of chronic active MS lesions as compared to NAWM
(Fig. 5a-l). In contrast, differences in axonal αKGDH
expression were not observed when comparing active
and inactive lesion areas with NAWM (Fig. 5e-h).
Taken together, these results indicate that the expression
of key glycolytic and TCA cycle enzymes is strongly
increased in the active rim of MS lesions. In the inactive
lesion center, expression of glycolytic enzymes is increased
in both astrocytes and axons, whereas the TCA cycle
enzymes show a differential expression pattern.
Reduced axonal αKGDH expression and activity in MS
lesions
In line with previous studies, we observed increased
expression of the mitochondrial marker porin in astro-
cytes and axons in both active and inactive lesions (data
Fig. 2 Axonal HK2 and PK expression in MS lesions. Immunofluorescent double staining of HK2 (a-c, green) or PK (e-g, green) and axons, labelled
by the pan-neurofilament marker SMI312 (red), illustrates increased HK2 and PK axonal colocalization. The number of colocalizing pixels was
quantified (d, h). *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 3 (See legend on next page.)
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not shown) [24, 46]. Despite an increased number of
mitochondria, αKGDH expression remained unaltered,
suggesting that αKGDH levels are reduced in axonal
mitochondria. Triple immunofluorescence staining of
αKGDH, porin and SMI312 demonstrated that αKGDH
expression was significantly reduced in mitochondria in
demyelinated axons as compared to mitochondria in
myelinated axons in NAWM (Fig. 6a-d). Importantly, mito-
chondrial αKGDH expression was reduced in dysfunctional
axons that were identified by synaptophysin accumulation
(Fig. 6e-i) (Additional file 4: Figure S3). Quantitative en-
zyme histochemistry demonstrated that αKGDH
NADH production capacity was markedly decreased in
inactive lesions (Fig. 6j-l) (Additional file 4: Figure S3).
To determine which factors underlie reduced axonal
expression and NADH production capacity of αKGDH
in MS lesions, we cultured human neuroblastoma cells
under various conditions. Demyelinated axons in MS
lesions are considered to be in a state of virtual hypoxia
[42]. Therefore, we cultured neuronal cells under
hypoglycaemic and hypoxic conditions. Hypoglycaemia
increased αKGDH mRNA levels, whereas hypoxia signifi-
cantly reduced αKGDH expression (Fig. 6m). Treatment
for 24 h with TNF-α and IFN-γ, pro-inflammatory cyto-
kines that are abundantly present in active MS lesions,
resulted in a small, but consistently decreased αKGDH
mRNA expression [3, 6]. Reactive oxygen species are
considered to play an important role in mitochondrial
dysfunction and associated axonal degeneration [30]. We
treated neurons with tertbutyl hydrogen peroxide (tbH2O2)
to induce oxidative stress and found slightly decreased
αKGDH levels (Fig. 6m).
In conclusion, we show that expression and activity of
mitochondrial αKGDH, one of the rate-limiting enzymes
of the TCA cycle, are reduced in chronically demyeli-
nated axons. Reduced expression of αKGDH correlates
with axonal damage and may be caused by hypoxic
conditions, inflammation and oxidative stress.
Discussion
This study provides a comprehensive overview of the
expression and activity of key glycolytic, TCA cycle
and lactate-metabolizing enzymes in MS lesions. We
showed that expression levels of various metabolic
enzymes were consistently upregulated in astrocytes
and to a lesser extent in axons in active MS lesions.
Astrocytes and axons in inactive MS lesions showed
elevated expression of glycolytic enzymes as compared
to NAWM. In inactive lesions, astrocytes express in-
creased levels of lactate-producing enzymes, whereas
the level of lactate-consuming enzymes was predomin-
antly upregulated in axons. Finally, we observed that
the expression of mitochondrial αKGDH was signifi-
cantly decreased in demyelinated axons and correlated
with axonal dysfunction.
Our immunohistochemical analyses revealed increased
expression of key glucose - metabolizing enzymes (GME)
in active MS lesions, suggesting that the activity of glyco-
lytic and TCA cycle pathways is increased. In fact, we
showed that αKGDH and LDH production capacities are
increased in active MS lesions. In line with these observa-
tions, previous studies showed that astrocytes and axons in
active MS lesions have an increased mitochondrial mass,
enhanced OxPhos activity and express a wide variety of es-
sential nutrient transporters [24, 29, 46]. Furthermore, im-
aging studies in MS patients indicate that both glucose and
lactate metabolism is increased in active MS lesions
[39, 41, 50]. Lactate levels were also found to be in-
creased in the CSF and serum of MS patients and to
correlate with disease progression [1, 35]. These studies
suggest that the changes in GME expression levels we
found are associated with alterations in the glycolytic
and TCA cycle fluxes.
We previously demonstrated increased expression of
nutrient transporters in reactive astrocytes in active MS
lesions [29]. Here we found that GME expression showed a
similar cellular distribution pattern as the nutrient trans-
porters. Active MS lesions are characterized by abundant
inflammation leading to enhanced cellular glucose metabol-
ism whereas in vitro experiments demonstrated that expos-
ure of astrocytes to pro-inflammatory cytokines increases
glucose uptake and TCA cycle flux to a higher extent
compared to neurons [4, 31]. Since protein synthesis takes
place at the neuronal cell body and axons can reside at a
great distance from the neuronal cell bodies, axonal struc-
tures cannot adapt protein expression as quickly as astro-
cytes, making them more dependent on the regulation of
activity rather than transcription of proteins. This may ex-
plain why the most prominent changes in GME expression
levels in active MS lesions were observed in astrocytes.
(See figure on previous page.)
Fig. 3 Astrocyte-axon lactate coupling in MS lesions. LDHA and LDHB proteins were moderately expressed in the NAWM (a,d) and inactive MS
lesions (c,f). In active MS lesions intense LDHA (b) and LDHB (e) immunoreactivity was observed. Insets show imunnofluorescence labeling of
LDHA (b, green) and LDHB (e) with the astrocytic marker GFAP (red). NAD+-dependent LDH activity was increased in active MS lesions but
decreased in inactive lesions compared to NAWM (g-i). The quantitative data are shown in (j). Quantification of immunofluorescence double
labeling of LDHA and LDHB with respectively GFAP (k) or SMI312 (l) in lesions as compared to NAWM. Staining of MCT2 (m, magenta), SMI312
(n, green), GFAP (o, red) and corresponding overlay (p) in inactive MS lesions. *P < 0.05, ***P < 0.001
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Fig. 4 (See legend on next page.)
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We observed marked astrocytic expression of enzymes
involved in glycolysis in chronic lesions suggesting that
astrocytes become more glycolytic in inactive MS lesions.
High glycolytic rates coincide with enhanced production
of lactate [45]. Here, we observed the same phenomenon
in MS lesions since the LDHA/LDHB ratio in astrocytes
was increased in inactive MS lesions as compared to sur-
rounding NAWM. Thus, astrocytes seem to favour lactate
production above utilization. Moreover, NAD+-dependent
LDH activity was decreased in inactive MS lesions,
which implies that the NADH-dependent LDH activity
(i.e. production of lactate) is increased. These results
are in line with previous studies which reported
enhanced lactate levels in inactive MS lesions and in-
creased astrocytic expression of the lactate transporter
MCT1 [29, 40].
In inactive MS lesions, axons upregulated expression
of glycolytic enzymes (HK2, PK) as well as TCA cycle
(See figure on previous page.)
Fig. 4 PDH, αKGDH and MDH expression in MS lesions. PDH (a, b), αKGDH (d,e) and MDH (g,h) expression was increased in active MS lesions as
compared to NAWM. Insets show that GFAP-positive astrocytes (red) colocalize with respectively PDH (b), αKGDH (e) and MDH (i, green). PDH (c)
and αKGDH (f) expression was relatively low in inactive MS lesions, whereas MDH (i) expression was increased as compared to NAWM. The
staining intensity of PDH, αKGDH, and MDH was significantly reduced in inactive lesions and the inactive center of chronic active lesions as compared to
active lesions and the active rim of chronic active lesions (j). PDH, αKGDH, and MDH immunoreactivity correlates with disease duration (k). –= strongly
reduced immunoreactivity as compared to NAWM; −= reduced immunoreactivity as compared to NAWM; +/−= similar immunoreactivity as compared to
NAWM, + = increased immunoreactivity as compared to NAWM, ++= strongly increased immunoreactivity as compared to NAWM. *P< 0.05, ***P< 0.001
Fig. 5 Axonal PDH, αKGDH and MDH expression in MS lesions. Immunofluorescence labelling of PDH (a-c), αKGDH (e-g) and MDH (i-k) in green
and SMI312-positive axonal structures in red. The axonal colocalization of PDH (d), αKGDH (h) and MDH (l) was quantified. *P < 0.05, **P < 0.01
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Fig. 6 Axonal αKGDH expression, regulation and activity in MS lesions. High magnification immunofluorescence staining of αKGDH (red), porin
(green) and SMI312 (magenta) (a-c). The quantitative data are shown in (d). Double labelling of synaptophysin (e,g, red) and αKGDH (f, h, green).
The total area stained for αKGDH was determined in synaptophysin-positive and synaptophysin-negative images (i). NAD+-dependent αKGDH
activity was reduced in inactive lesions (k) as compared to NAWM (j). The quantitative data are shown in (l). Culture of human neuroblastoma
cells under hypoxia or in the presence of ROS or TNF-α and IFN-γ reduced αKGDH mRNA expression (m). *P < 0.05, **P < 0.01
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enzymes (PDH and MDH) suggesting that axonal
glucose metabolism is increased. In addition to glucose,
axons can use lactate to fulfil their energetic needs [22].
Here, we showed that axons in inactive MS lesions have a
lower LDHA/LDHB ratio as compared to NAWM, result-
ing in increased lactate utilization by demyelinated axons.
Moreover, we found that demyelinated axons express
abundant MCT2, despite an overall decrease in protein
expression [29]. Under normal conditions, oligodendro-
cytes supply axons with lactate, however most oligoden-
drocytes are lost during the inflammatory attack in MS
lesions [16, 22]. Our data suggests that astrocytes in
inactive MS lesions may supply demyelinated axons with
lactate. Future studies are needed to assess the functional-
ity of astrocyte-axon coupling in vivo and should be
directed to gain more insight in the role of lactate under
pathological conditions.
Demyelinated axons are highly dependent on a sufficient
supply of energy to maintain proper conduction, which
may explain the upregulation of GME expression in demye-
linated axons. Remarkably, we observed reduced αKGDH
expression and NADH production capacity in axonal mito-
chondria in MS lesions. Double labelling of αKGDH with
synaptophysin revealed that αKGDH expression is
particularly reduced in axons with signs of impaired
axonal transport. Interestingly, Mahad et al. previously
observed decreased complex IV activity in a subset of
dysfunctional axons [24]. Impaired αKGDH function
can contribute to these changes in complex IV activity.
As αKGDH is one of the rate-limiting enzymes of mito-
chondrial metabolism, reduced αKGDH activity can
result in impaired mitochondrial energy metabolism
and thereby contribute to neurodegeneration, which
has been demonstrated in various studies [18, 21, 43].
Finally, we show that αKGDH activity and expression
can be regulated upon exposure to a variety of stimuli
[10, 27]. We found that, free radicals, TNF-α and IFN-
γ, which are abundantly produced in active MS lesions,
reduce αKGDH expression in vitro [3, 6, 14]. In inactive
MS lesions, demyelinated axons are reported to be in a
state of virtual hypoxia, which may also contribute to
decreased αKGDH expression [42].
Conclusions
In conclusion, our findings imply that in addition to
reduced OxPhos activity, other key bioenergetic pro-
cesses such as, glycolysis, TCA cycle and lactate me-
tabolism are affected in MS lesions.
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